Posted by Michael Wonder on 25 Jun 2020
The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany
15 June 2020 - Payers are increasingly calling for the value of new drugs to be measured explicitly.
The researchers analysed how the availability of drug quality ratings by health technology assessment agencies affects the adoption of new drugs by physicians in Germany.
They combined data from drug quality ratings, promotional spending, and a physician panel.
